Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Phase 3 Completed 94 enrolled H. Lundbeck A/S

NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent patients with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD

Timeline

Start: 2017-03-01
Primary completion: 2020-04-16
Completion: 2020-04-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vortioxetine	Unknown	5 mg	Oral
Subject	Vortioxetine	Unknown	10 mg	Oral
Subject	Vortioxetine	Unknown	15 mg	Oral
Subject	Vortioxetine	Unknown	20 mg	Oral

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Summary

Timeline

Drugs

Indications